Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?

医学 2型糖尿病 药方 糖尿病 内科学 优势比 疾病 利拉鲁肽 逻辑回归 内分泌学 药理学
作者
Sebastian Barth,Karel Kostev,Magdalene Krensel,Elke Mathey,Wolfgang Rathmann
出处
期刊:Experimental and Clinical Endocrinology & Diabetes [Thieme Medical Publishers (Germany)]
卷期号:131 (03): 153-161 被引量:1
标识
DOI:10.1055/a-1927-4454
摘要

Abstract Objectives To analyze whether prescription use of GLP-1RA and SGLT2i in individuals with type 2 diabetes with cardiovascular disease (CVD) has increased after the ADA/EASD consensus guidelines (2018) in a German Real-World setting and which clinical characteristics are associated with prescription use of these drugs. Methods The Disease Analyzer database (IQVIA) comprises a representative panel of 1,373 general practitioners, diabetologists, and cardiologists throughout Germany (01/2015-12/2020: 12.6 million patients). Newly diagnosed type 2 diabetes (n=45,531) was identified by ICD-10 codes (E11). Matching (1:1) on practice specialty, sex, age, and year of diabetes diagnosis was performed for CVD. Logistic regression models were fitted to obtain adjusted odds ratios (OR) for characteristics associated with prescription use (median follow-up: 1.9 years). Results Overall, 35% of patients (n=16,006) were treated with glucose-lowering drugs during the first year after type 2 diabetes diagnosis (HbA1c≥7.0%: 80%). GLP-1RA (2.4%) and SGLT2i (8.5%) were rarely prescribed. After the consensus, use of GLP-1RA and SGLT2i increased, however, almost independently of pre-existing CVD (12/2019-11/2020 vs. 12/2017-11/2018: yes, no): GLP-1RA: from 5.7 to 9.2%, 5.2 to 7.6%; SGLT2i: from 13.9 to 20.4%, 12.1 to 16.6%. Among cardiovascular risk factors, the largest OR for GLP-1RA was for obesity (4.5; 95%CI: 3.2–6.3). CVD was moderately related with SGLT2i (1.45; 1.32–1.60) and GLP-1RA (1.35; 1.08–1.69) prescriptions. A weak association was observed between SGLT2i and heart failure (1.18; 95%CI: 1.05–1.32). Conclusion National prescription use of GLP-1RA and SGLT2i did not come close to the recommendation in subjects with CVD issued by the 2018 ADA/EASD consensus.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
Liufgui应助嗯哼采纳,获得10
1秒前
鹅鹅完成签到,获得积分10
1秒前
wanci应助飞飞加油呀采纳,获得10
1秒前
Orange应助yang采纳,获得10
1秒前
1秒前
1秒前
完美世界应助甘愿采纳,获得10
2秒前
2秒前
3秒前
3秒前
Denning发布了新的文献求助10
4秒前
4秒前
貔貅完成签到,获得积分10
4秒前
5秒前
Liufgui应助氯化钾芝士采纳,获得10
5秒前
飞天817发布了新的文献求助10
5秒前
活力臻发布了新的文献求助10
6秒前
依然小爽完成签到,获得积分10
6秒前
Flynn完成签到,获得积分10
6秒前
852应助沐晴采纳,获得30
7秒前
ff发布了新的文献求助10
7秒前
赶路人完成签到,获得积分10
8秒前
崔懿龍发布了新的文献求助10
9秒前
9秒前
9秒前
小张发布了新的文献求助10
10秒前
Liufgui应助徐智秀采纳,获得20
10秒前
焦糖发布了新的文献求助20
10秒前
薇薇快跑完成签到,获得积分20
11秒前
Orange应助独特的凝云采纳,获得10
11秒前
11秒前
12秒前
万能图书馆应助轻歌水越采纳,获得10
12秒前
量子星尘发布了新的文献求助10
12秒前
lm发布了新的文献求助10
14秒前
15秒前
yewungs完成签到,获得积分10
15秒前
薇薇快跑发布了新的文献求助10
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Economic Geography and Public Policy 900
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021